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Many studies have reported suppression of the 
hypothalamic-pituitary-adrenal (HPA) axis following 
use of corticosteroids. Thus, HPA axis suppression 
has been used to assess the systemic bioavailability 
of inhaled corticosteroids, permitting in vivo micro- 
gram per microgram comparisons between various 
compounds (14). A number of factors, however, 
influence HPA-axis suppression with inhaled cortico- 
steroids (Table 1). The potency of the compound, 
dosage and duration of treatment all play a role in 
action on the HPA axis, while a confounding factor 
in many studies is also prior long-term, oral steroid 
use (5). In addition, the study population is import- 
ant, since healthy volunteers absorb more of an 
inhaled dose into the lung compared with asthma 
patients, possibly because of different airway patency. 
Thus, at comparable inhaled doses, greater systemic 
bioavailability from the lung has been shown in 
studies in healthy volunteers, compared to asthmat- 
ics. It is also known that there is significant 
inter-individual variability of side-effects in different 
populations taking a given dose of a glucocorticoid. 
However, it is not clear whether this variability 
reflects pharmacokinetic, pharmacodynamic and/or 
genetic differences. 
Tests of Adrenal Function 
Adrenal function tests (6) can either assess basal 
secretory function (morning serum cortisol, 24-hr 
serum cortisol profile, or 24-hr urinary free cortisol) 
or involve stimulation testing (e.g. short [68min] 
or long [6-8 hr] exogenous adrenocorticotrophic 
hormone [ACTH], metyrapone or insulin-induced 
hypoglycaemia). Holt et al. (7) examined the effects of 
beclomethasone dipropionate (BDP), 2000 ,ug/day for 
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14 days, in 12 healthy volunteers using 4 different 
tests of HPA axis function. It was found that urinary 
free cortisol and single-dose metyrapone tests were 
the most sensitive to assess the acute effects of inhaled 
corticosteroids on HPA axis function. The ACTH 
test was the least sensitive, but this might be expected 
as 14 days is probably not long enough to cause 
adrenocortical atrophy. 
When analysing the results of HPA axis suppres- 
sion with inhaled corticosteroids, it is important to 
define the study end-points as well as the clinical 
implications of the findings. For example, even 
though there may be statistically significant HPA axis 
suppression, the functional status of the HPA axis 
in most instances is normal. Low-medium dosing 
with inhaled corticosteroids results in physiological 
perturbation and partial suppression of HPA axis 
function; clinically relevant changes would only be 
expected, however, when there is complete HPA 
suppression (adrenocortical atrophy) following high 
dose, long-term treatment. 
The clinical relevance of HPA axis suppression is 
illustrated in a study following single-dose inhalation 
of fluticasone propionate (either 250, 500 or 1OOOpg) 
or budesonide (8OOpg) at 22.00 h in healthy 
volunteers (8). Plasma cortisol profiling was 
performed every 2 hours, morning cortisol levels 
were measured and areas under the curve (AUC) 
were calculated. The study design exaggerated HPA 
suppression with Auticasone propionate, as high 
doses were used and inhalation was administered at 
the end of the day. However, the results illustrate 
several important points. First, there was a dose- 
related reduction in mean morning cortisol levels and 
AUC following evening administration of fluticasone 
propionate. Second, consistent with in vitro studies, 
fluticasone propionate was found to be about twice as 
potent as budesonide on a microgram per microgram 
basis. Finally, and possibly of considerable clinical 
relevance, cortisol suppression was only partial at the 
low and medium doses of fluticasone propionate. 
Hence, from a physiological standpoint, the inhaled 
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TABLE 1. Factors influencing the incidence of adrenal 
suppression with inhaled corticosteroids 
l Characteristic of specific compounds 
l Dose frequency and timing of administration 
l Duration of treatment 
l Prior oral steroid 
l Population studies: 
Healthy vs. patients with asthma 
Children vs. adults 
l Significant inter-individual variability 
drug supplies a small proportion of the daily gluco- 
corticoid requirement, while endogenous cortisol 
production is largely preserved. 
High-dose Inhaled Corticosteroids and 
HPA Axis Suppression 
Brown et al. (9) evaluated morning cortisol, urinary 
free cortisol and short ACTH stimulation testing in 
78 asthma patients who had been treated with a 
median dose of 1600 ,ug of either BDP or budesonide 
for a duration of 13 months. Approximately 30% of 
these patients had received prior systemic steroids, 
but had not received such treatment within 6 months 
of HPA axis evaluation. The results of this study 
showed that 80% of patients did not exhibit HPA axis 
suppression. In the remaining 20% of patients, HPA 
axis suppression was correlated with the duration of 
high dose inhaled corticosteroids treatment, as well as 
prior systemic steroid use. It is possible that in this 
study, patients with long-term steroid exposure could 
have had suppressed HPA axis function, which was 
sustained by the high-dose inhaled corticosteroid 
treatment. 
ASSESSMENT OF SYSTEMIC CORTICOSTEROID ACTIVITY 33 
Summary 
The potency of the inhaled corticosteroid, dose, 
duration of treatment, and the study subject receiving 
treatment all play a role in the effects observed on the 
HPA axis. At low/medium doses of inhaled cortico- 
steroids, where there is minimal/modest HPA axis 
suppression, there should be no risk of adrenal crisis 
even under stressful conditions (6). Thus, the risk of 
acute adrenal insufficiency, culminating in adrenal 
crisis, in patients taking inhaled steroids is extremely 
unlikely. 
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